References
- O’Brien S. MIMS guide to chronic myeloid leukaemia. London, UK (2000).
- Garside R, Round A, Dalziel K, Stein K, Royle P. The effectiveness and cost–effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. Health Technol. Assess.6, 1–151 (2002).
- Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med.346, 645–652 (2002).
- Aoki E, Kantarjian H, O’Brien S et al. Correlation of different responses to imatinib on survival of patients with chronic myelogenous leukemia in accelerated and blast phase. Presented at: 46th Annual Meeting of the American Society of Hematology. San Diego, CA, USA, 4–7 December (2004) (Abstract 1103).
- Druker B, Guilhot F, O’Brien S et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355, 2408–2417 (2006).
- Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.349, 1423–1432 (2003).
- Kantarjian H, Rousselot P, Pasquini R et al. Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood109, 5143–5150 (2007).
- Quintas-Cardama A, Kantarjian H, O’Brien S et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol.25, 3908–3914 (2007).
- Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N. Engl. J. Med.354, 2623–2624 (2006).
- Levy AR, Szabo SM, Tabberer M, and Davis C. Utility values for health states for chronic myelogenous leukaemia (CML): estimates from laypersons in Australia, the United Kingdom (UK) and Canada. Presented at: ISPOR European Conference. Dublin, Ireland, 20–23 October 2007.
- Taylor M. The relationship between short-term response and long-term costs and benefits in the treatment of chronic myelogenous leukaemia. Presented at: ISPOR International Conference. Arlington, VA, USA, 21–25 May 2007.
- Holowiecki J, Konopka L, Kopera M et al. ; Polish Adult Leukemia Group. Efficacy of imatinib in patients with chronic myeloid leukemia in late chronic phase who are hematologically or cytogenetically resistant or refractory to interferon α. Phase II study of the Polish Adult Leukemia Group. Presented at: 45th Annual Meeting and Exposition of the American Society of Hematology. San Diego, CA, USA, 6–9 December 2003.
- Shah N, Kim D, Kantarjian H et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol.26, 3204–3212 (2008).
Website
- Department of Health and Ageing, Australian Government Canberra. Schedule of Pharmaceutical Benefits. www.pbs.gov.au/html/home (Accessed 5 November 2008)